EGFR and non-small cell lung carcinoma: Atezolizumab in combination with carboplatin, paclitaxel, and bevacizumab significantly improved progression-free survival (PFS) in EGFR+/ALK+ NSCLC patients in the IMpower150 trial (45), compared to chemotherapy in combination with bevacizumab, indicating that EGFR-mutant LUAD patients are reversible regarding resistance to ICIs at various stages of the disease.